Adam Siddiqui-Jain

6.2k total citations · 1 hit paper
41 papers, 4.7k citations indexed

About

Adam Siddiqui-Jain is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Adam Siddiqui-Jain has authored 41 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 12 papers in Hematology and 10 papers in Oncology. Recurrent topics in Adam Siddiqui-Jain's work include DNA and Nucleic Acid Chemistry (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Protein Degradation and Inhibitors (5 papers). Adam Siddiqui-Jain is often cited by papers focused on DNA and Nucleic Acid Chemistry (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Protein Degradation and Inhibitors (5 papers). Adam Siddiqui-Jain collaborates with scholars based in United States, Australia and Canada. Adam Siddiqui-Jain's co-authors include Laurence H. Hurley, David J. Bearss, Cory L. Grand, Sean O’Brien, Kenna Anderes, Denis Drygin, William G. Rice, Chris Proffitt, Caroline B. Ho and Nicole Streiner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Adam Siddiqui-Jain

41 papers receiving 4.7k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c- MYC transcription

2002 1.9k citations Adam Siddiqui-Jain, Cory L. Grand et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam Siddiqui-Jain United States	17	4.2k	563	347	181	157	41	4.7k
Sergei Gryaznov United States	41	3.9k 0.9×	344 0.6×	278 0.8×	146 0.8×	26 0.2×	107	4.7k
Jennifer L. Stamos United States	14	2.2k 0.5×	788 1.4×	566 1.6×	210 1.2×	195 1.2×	17	3.3k
Daniel P. Sutherlin United States	23	2.3k 0.6×	832 1.5×	470 1.4×	343 1.9×	154 1.0×	32	3.1k
A.E. Prota Switzerland	33	2.6k 0.6×	935 1.7×	1.5k 4.2×	186 1.0×	185 1.2×	72	4.2k
Denis Drygin United States	18	2.2k 0.5×	600 1.1×	225 0.6×	232 1.3×	215 1.4×	41	2.7k
John G. Moffat United States	20	1.9k 0.4×	809 1.4×	323 0.9×	266 1.5×	250 1.6×	37	2.8k
Fernando Cabral United States	36	2.7k 0.6×	1.4k 2.4×	234 0.7×	300 1.7×	104 0.7×	81	4.1k
Gerhard Siemeister Germany	32	2.2k 0.5×	959 1.7×	430 1.2×	594 3.3×	117 0.7×	68	3.3k
Roxana E. Iacob United States	24	1.6k 0.4×	679 1.2×	267 0.8×	132 0.7×	54 0.3×	34	2.4k
Simon Bergqvist United States	25	1.5k 0.3×	599 1.1×	233 0.7×	327 1.8×	72 0.5×	35	2.3k

Countries citing papers authored by Adam Siddiqui-Jain

Since Specialization

Citations

This map shows the geographic impact of Adam Siddiqui-Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Siddiqui-Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Siddiqui-Jain more than expected).

Fields of papers citing papers by Adam Siddiqui-Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Siddiqui-Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Siddiqui-Jain. The network helps show where Adam Siddiqui-Jain may publish in the future.

Co-authorship network of co-authors of Adam Siddiqui-Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Siddiqui-Jain. A scholar is included among the top collaborators of Adam Siddiqui-Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Siddiqui-Jain. Adam Siddiqui-Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matsumura, Yuta, Ethika Tyagi, Jason M. Foulks, et al.. (2019). Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models. Molecular Cancer Therapeutics. 18(12_Supplement). C081–C081. 1 indexed citations

Peterson, Peter, Clifford J. Whatcott, Adam Siddiqui-Jain, et al.. (2017). TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency. Blood. 130(Suppl_1). 937–937. 2 indexed citations

Peterson, Peter, et al.. (2016). The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease. Blood. 128(22). 263–263. 4 indexed citations

Peterson, Peter, Clifford J. Whatcott, Adam Siddiqui-Jain, et al.. (2016). Abstract 3728: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations. Cancer Research. 76(14_Supplement). 3728–3728. 1 indexed citations

Smith, B. Douglas, Steven L. Warner, Clifford J. Whatcott, et al.. (2015). An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function.. Journal of Clinical Oncology. 33(15_suppl). 7062–7062. 8 indexed citations

Peterson, Peter, Clifford J. Whatcott, Adam Siddiqui-Jain, et al.. (2015). The MCL-1 targeting effect of alvocidib potentiates the activity of cytarabine and mitoxantrone in a time-sequential regimen in AML. Clinical Lymphoma Myeloma & Leukemia. 15. S18–S18. 2 indexed citations

Peterson, Peter, et al.. (2015). ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease. Blood. 126(23). 273–273. 7 indexed citations

Siddiqui-Jain, Adam, Joshua Bliesath, Mayuko Omori, et al.. (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Molecular Cancer Therapeutics. 11(4). 994–1005. 86 indexed citations

Pierre, Fabrice, Adam Siddiqui-Jain, Nicole Streiner, et al.. (2012). Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorganic & Medicinal Chemistry Letters. 22(9). 3327–3331. 28 indexed citations

10.

Bliesath, Joshua, Nanni Huser, Mayuko Omori, et al.. (2012). Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Letters. 322(1). 113–118. 59 indexed citations

11.

Drygin, Denis, Caroline B. Ho, Mayuko Omori, et al.. (2011). Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochemical and Biophysical Research Communications. 415(1). 163–167. 57 indexed citations

12.

Pierre, Fabrice, Eric Stefan, Adam Siddiqui-Jain, et al.. (2011). 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorganic & Medicinal Chemistry Letters. 21(22). 6687–6692. 46 indexed citations

13.

Pierre, Fabrice, Sean O’Brien, Mustapha Haddach, et al.. (2011). Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties. Bioorganic & Medicinal Chemistry Letters. 21(6). 1687–1691. 28 indexed citations

14.

Haddach, Mustapha, Fabrice Pierre, Jerome Michaux, et al.. (2011). Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs. Bioorganic & Medicinal Chemistry Letters. 22(1). 45–48. 15 indexed citations

15.

Drygin, Denis, Amy Lin, Josh Bliesath, et al.. (2010). Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth. Cancer Research. 71(4). 1418–1430. 462 indexed citations

16.

Siddiqui-Jain, Adam, Denis Drygin, Nicole Streiner, et al.. (2010). CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Research. 70(24). 10288–10298. 421 indexed citations

17.

Drygin, Denis, Adam Siddiqui-Jain, Sean O’Brien, et al.. (2009). Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis. Cancer Research. 69(19). 7653–7661. 462 indexed citations

18.

Hurley, Laurence H., Daniel D. VonHoff, Adam Siddiqui-Jain, & Danzhou Yang. (2006). Drug Targeting of the c-MYC Promoter to Repress Gene Expression via a G-Quadruplex Silencer Element. Seminars in Oncology. 33(4). 498–512. 103 indexed citations

19.

Rice, William G., Michael K. Schwaebe, Adam Siddiqui-Jain, et al.. (2005). Clinical development of CX-3543, a novel multi-targeting antitumor agent. Journal of Clinical Oncology. 23(16_suppl). 3206–3206. 7 indexed citations

20.

Siddiqui-Jain, Adam, Cory L. Grand, David J. Bearss, & Laurence H. Hurley. (2002). Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c- MYC transcription. Proceedings of the National Academy of Sciences. 99(18). 11593–11598. 1905 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact